ArticleBMC cancer2025
Machine learning based identification of an amino acid metabolism related signature for predicting prognosis and immune microenvironment in pancreatic cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial Intelligence for the Diagnosis and Management of Cancers: Potentials and Challenges.MedComm · 2025Review
- Integration of bulk and single-cell transcriptomic data reveals a novel signature related to liver metastasis and basement membrane in pancreatic cancer.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer is a highly aggressive neoplasm characterized by poor diagnosis. Amino acids play a prominent role in the occurrence and progression of pancreatic cancer as essential building blocks for protein synthesis and key regulators of cellular metabolism. Understanding the interplay between pancreatic cancer and amino acid metabolism offers potential avenues for improving patient clinical outcomes.
methodsA comprehensive analysis integrating 10 machine learning algorithms was executed to pinpoint amino acid metabolic signature. The signature was validated across both internal and external cohorts. Subsequent GSEA was employed to unveil the enriched gene sets and signaling pathways within high- and low-risk subgroups. TMB and drug sensitivity analyses were carried out via Maftools and oncoPredict R packages. CIBERSORT and ssGSEA were harnessed to delve into the immune landscape disparities. Single-cell transcriptomics, qPCR, and Immunohistochemistry were performed to corroborate the expression levels and prognostic significance of this signature.
resultsA four gene based amino acid metabolic signature with superior prognostic capabilities was identified by the combination of 10 machine learning methods. It showed that the novel prognostic model could effectively distinguish patients into high- and low-risk groups in both internal and external cohorts. Notably, the risk score from this novel signature showed significant correlations with TMB, drug resistance, as well as a heightened likelihood of immune evasion and suboptimal responses to immunotherapeutic interventions.
conclusionOur findings suggested that amino acid metabolism-related signature was closely related to the development, prognosis and immune microenvironment of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.